Abstract

The complexity as well as heterogeneity of cancer possess botherations for cancer therapy. In the form of a class of single‑chain peptides, insulin‑like growth factors (IGFs) possess pivotal parts in cell growth, proliferation, differentiation in addition to metabolic regulation. IGFs facilitates the proliferation, migration, along with possess the invasive capability of tumor cells as well as are intricately correlated with inimical prognosis. Furthermore, IGFs possess the capacity of affecting the crosstalk amongst immune cells in the tumor micromilieu resulting in immune evasion. Additionally, the activation of signals correlated with IGFs modulates the resistance of tumor cells to chemotherapeutic drugs. With the escalating incidence of tumor processes, the will in reference to generation of innovative treatments is assuming greater urgency. This is an exhaustive narrative article regarding the molecular biological mechanistic modes of IGFs in tumorigenesis as well as the generation of innovative treatments associated to targeting IGFs, with the optimism of yielding novel understanding into cancer therapy. This is subsequent to our earlier review on the advancements in the therapy of advanced ovarian cancer(OC) ,programmed death (PD1) /programmed death ligand1( PDL1) pathway and exhaustive review on high grade serous ovarian carcinoma (HGSOC’s) –etiology, emphasizing on intra tumor heterogeneity(ITH); homologous recombination repair (HRR) pathway ; homologous recombination deficiency(HRD) and therapy with PARP hampering agents following neoadjuvant chemotherapy (NACT) -with significance of generation of platinum-resistant(PROC) in addition to tackling inimical toxicity sequelae correlated with PARP hampering agents& platinum-based chemotherapy & recently further updated overcoming such issues by utilizing antibody-drug conjugates for PROC & parts of crosstalk amongst endoplasmic reticulum (ER) stress and ferroptosis.